Literature DB >> 27529670

Prognostic Role of the Expression of Invasion-Related Molecules in Glioblastoma.

József Virga1, László Bognár1, Tibor Hortobágyi2, Gábor Zahuczky3, Éva Csősz4, Gergő Kalló4, Judit Tóth5, Gábor Hutóczki1, Judit Reményi-Puskár1, László Steiner3, Almos Klekner1.   

Abstract

Background Glioblastoma multiforme (GBM) is the most common malignant disease of the central nervous system. Its prognosis is unfavorable, and the median overall survival of patients is 16 to 24 months. The main cause of the poor survival data are the extensive invasion of cancer cells to the neighboring parenchyma, thus leading to inevitable local recurrence. The extracellular matrix (ECM) is a known factor in tumor invasion, and differences in the ECM of nontumor brain and glioblastoma has been proven. Methods In this research, 20 invasion-related expressions of ECM components were determined in 26 GBM flash-frozen samples using quantitative reverse transcription-polymerase chain reaction and proteomic measurements. Expression data were then set against the survival data of the patients. Results Significant alterations between groups with different survival rates could not be established in the individual evaluation of the expression level of the selected molecules. However, statistical analysis of the expression pattern of invasion-related molecules revealed a correlation with prognosis. The positive predictive values of the messenger RNA (mRNA) and the proteomic expression studies were 0.85 and 0.89, respectively. The receiver operation characteristic value was 0.775 for the mRNA expression data and 0.875 for the protein expression data. Furthermore, a group of molecules, including brevican, cadherin-12, integrin β1, integrin α3, laminin α4, and laminin β1, that play a prominent role in invasion were identified. Conclusions Joint assessment of the expression of invasion-related molecules provides a specific invasion spectrum of the tumor that correlates with the survival of glioblastoma patients. Using statistical classifiers enables the adoption of an invasion spectrum as a considerably accurate prognostic factor while gaining predictive information on potential molecular oncotherapeutic targets at the same time. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27529670     DOI: 10.1055/s-0036-1584920

Source DB:  PubMed          Journal:  J Neurol Surg A Cent Eur Neurosurg        ISSN: 2193-6315            Impact factor:   1.268


  6 in total

1.  Is Integrin Subunit Alpha 2 Expression a Prognostic Factor for Liver Carcinoma? A Validation Experiment Based on Bioinformatics Analysis.

Authors:  Liang Zhang; Yi Huang; JunJun Ling; Wenlei Zhuo; Zhen Yu; Yunbo Luo; Yi Zhu
Journal:  Pathol Oncol Res       Date:  2018-12-04       Impact factor: 3.201

2.  MiR-539 inhibits proliferation and migration of triple-negative breast cancer cells by down-regulating LAMA4 expression.

Authors:  Zhi-Xue Yang; Bo Zhang; Jinrong Wei; Guo-Qin Jiang; Yan-Lin Wu; Bing-Jing Leng; Chun-Gen Xing
Journal:  Cancer Cell Int       Date:  2018-01-30       Impact factor: 5.722

3.  Pathophysiology of Meningioma Growth in Pregnancy.

Authors:  Tibor Hortobágyi; János Bencze; Balázs Murnyák; Mahan C Kouhsari; László Bognár; György Marko-Varga
Journal:  Open Med (Wars)       Date:  2017-07-13

4.  Novel Linear Peptides with High Affinity to αvβ3 Integrin for Precise Tumor Identification.

Authors:  Yi Ma; Guanhua Ai; Congying Zhang; Menglu Zhao; Xue Dong; Zhihao Han; Zhaohui Wang; Min Zhang; Yuxi Liu; Weidong Gao; Siwen Li; Yueqing Gu
Journal:  Theranostics       Date:  2017-04-06       Impact factor: 11.556

5.  A Tumor-Homing Peptide Platform Enhances Drug Solubility, Improves Blood-Brain Barrier Permeability and Targets Glioblastoma.

Authors:  Choi-Fong Cho; Charlotte E Farquhar; Colin M Fadzen; Benjamin Scott; Pei Zhuang; Niklas von Spreckelsen; Andrei Loas; Nina Hartrampf; Bradley L Pentelute; Sean E Lawler
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.639

Review 6.  Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.

Authors:  Laure Malric; Sylvie Monferran; Julia Gilhodes; Sabrina Boyrie; Perrine Dahan; Nicolas Skuli; Julie Sesen; Thomas Filleron; Aline Kowalski-Chauvel; Elizabeth Cohen-Jonathan Moyal; Christine Toulas; Anthony Lemarié
Journal:  Oncotarget       Date:  2017-08-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.